Clinical trials
Pancreatic Adenocarcinoma Advanced or Metastatic clinical trials
Below are recruiting pancreatic adenocarcinoma advanced or metastatic clinical trials, each written for real people, not researchers. We’re tracking 3,839 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07446452RecruitingPhase 2
Combination treatment for HER2-low advanced breast cancer
This trial tests a combination of two drugs, disitamab vedotin and bevacizumab, for people with a specific type of advanced breast cancer called HER2-low. It is designed for those who have already been treated with a drug called T-DXd and need further options.
Nanjing, JiangsuAges 18–75 - NCT07451795RecruitingPhase 2
SHR-1701 with targeted radiation for advanced prostate cancer
This trial tests a new drug called SHR-1701 combined with a precise type of radiation (SBRT) for men with prostate cancer that has spread and is no longer responding to hormone therapy. The goal is to see if this combination can help control the cancer.
FujianAges 18–80 - NCT07445412Recruiting
Liver regeneration study for patients with small future liver remnant
This trial tests techniques to help the liver grow before surgery in people who have a liver tumor and whose future liver remnant is too small. The goal is to make the liver big enough to safely remove the tumor.
Bologna, BolognaAges 18 years+ - NCT06793553RecruitingPhase 2
Induction chemo then immunotherapy for PD-L1 positive triple negative breast cancer
This trial tests a two-step approach: first a short course of chemotherapy (paclitaxel and bevacizumab), followed by a combination of immunotherapy (atezolizumab) and a different chemotherapy (nab-paclitaxel). It's for people with advanced triple-negative breast cancer that has spread or cannot be removed, and whose tumors have a specific marker called PD-L1. The goal is to see if this sequence works better than standard treatments.
Koto-ku, 3-8-31, TokyoAges 18 years+ - NCT05749900RecruitingPhase 1/Phase 2
First-line antibody, chemo, and immunotherapy for HER2 bile duct cancer
This trial studies a combination of trastuzumab (an antibody), gemcitabine and cisplatin (chemo), plus nivolumab (immunotherapy) as the first treatment for advanced HER2-positive biliary tract cancer. It may help shrink tumors and improve outcomes by targeting HER2 and boosting the immune system.
SeoulAges 19 years+ - NCT07440290RecruitingPhase 2/Phase 3
Dabrafenib and trametinib for BRAF V600 cancers
This trial tests two targeted drugs (dabrafenib and trametinib) for patients whose cancer has a specific change in the BRAF gene called V600. These drugs work together to block signals that help the cancer grow. The trial is for children, teenagers, and adults with many types of cancer, except for a few common ones that already have approved treatments.
BelfastAges 1 year+ - NCT07441889RecruitingPhase 1/Phase 2
HER2-targeting immune cells for metastatic breast and prostate cancer
This trial tests a new treatment using specially designed immune cells that target HER2, a protein found on some cancer cells. It is for people with metastatic breast or prostate cancer that has worsened after prior treatments.
Charlottesville, VirginiaAges 18 years+ - NCT07439120RecruitingEarly Phase 1
Testing a new radioactive drug for advanced solid tumors
This trial tests a new radioactive drug called 68Ga/177Lu-BRP-020063 in people with advanced solid tumors, especially bladder or breast cancer. The drug seeks out Nectin-4 on cancer cells, helping doctors see and potentially treat the tumors. The goal is to check that the drug is safe and tolerable.
ShanghaiAges 18 years+ - NCT07443020RecruitingPhase 1
Fast immune cells for fluid build-up from cancer
This trial tests a treatment using your own immune cells (T cells) to fight cancer that has spread to the lining of the lung and is causing fluid buildup. It may help if other standard treatments have stopped working.
Pittsburgh, PennsylvaniaAges 18–79 - NCT07434947Recruiting
Rehabilitation benefits for advanced lung cancer after treatment
This trial tests whether a rehabilitation program can improve daily function and quality of life for people with advanced non-small cell lung cancer whose disease has been stable for at least 6 months. It aims to find the best way to measure the benefits of physical activity and support, so patients can feel better in their everyday lives.
AnnecyAges 18 years+ - NCT07426094RecruitingPhase 2/Phase 3
Boosting radiation for prostate cancer in lymph nodes
This trial tests whether giving higher radiation doses to the prostate and pelvic lymph nodes is more effective than treating only the prostate. You may benefit if your prostate cancer has spread to nearby lymph nodes but not to bones or other organs, and you are getting hormone therapy.
Zamość, Lublin VoivodeshipAges 18 years+ - NCT07433673RecruitingPhase 2
Gemcitabine, cisplatin, nab-paclitaxel, and cemiplimab for locally advanced bile duct cancer
This trial tests a combination of four drugs to see if they shrink locally advanced bile duct or gallbladder cancer that cannot be removed surgically. It is for people who have not had prior treatment for this cancer.
New York, New YorkAges 18 years+ - NCT07430202RecruitingPhase 1
Vaccine plus drug combination for advanced fibrolamellar carcinoma
This study tests a new vaccine (a shot that may help your immune system attack cancer cells) combined with a glutamine-blocking drug (DRP-104) and two immunotherapy drugs (nivolumab and ipilimumab) for advanced fibrolamellar carcinoma. It aims to see if this combination can shrink tumors or slow their growth.
Baltimore, MarylandAges 12 years+ - NCT07426822RecruitingPhase 2
Preventing Rash and Diarrhea with Capivasertib for Breast Cancer
This trial tests whether giving a combination of the drugs capivasertib and fulvestrant, along with medicines to prevent rash and diarrhea, can help treat hormone receptor-positive breast cancer that has a PIK3CA, AKT1, or PTEN change. It's for people whose cancer has spread or is locally advanced and can't be removed with surgery.
New Haven, ConnecticutAges 18 years+ - NCT06023212RecruitingPhase 1/Phase 2
Tranexamic acid to prevent bleeding in spine surgery for lung cancer
This trial tests if a medicine called tranexamic acid can help reduce bleeding during surgery for lung cancer that has spread to the spine. It may be an option if you have a single tumor in your spine and are having separation surgery.
Hangzhou, ZhejiangAges 10–80 - NCT07425002Recruiting
Precision Oncology Study in Breast Cancer (PRISM)
This study looks at tumor tissue from people with breast cancer, including those with brain metastases. It aims to learn more about the genetic changes in the cancer to help guide future treatments.
Dublin, LeinsterAges 18 years+ - NCT07417189RecruitingPhase 1/Phase 2
Study of ABSK141 for advanced solid tumors with KRAS G12D mutation
This study tests a new drug called ABSK141 for people with advanced solid tumors that have a specific mutation called KRAS G12D. It aims to see if the drug can shrink or control the cancer, and it has different phases for different groups of patients.
ShanghaiAges 18 years+ - NCT07422753RecruitingPhase 2
TACE with immunotherapy drugs for advanced liver cancer
This trial tests a combination of TACE (a procedure that blocks blood supply to the tumor) plus three immunotherapy drugs (sintilimab, bevacizumab, ipilimumab) for people with advanced liver cancer that cannot be removed by surgery. The goal is to see if this combination works better than TACE alone.
Hangzhou, ZhejiangAges 18–75 - NCT07423078RecruitingPhase 2
Larynx preservation trial for advanced throat cancer
This trial tests a new approach to treat throat cancer while trying to preserve your larynx (voice box). It combines chemotherapy drugs and an immunotherapy drug before surgery or radiation. The goal is to see if this can help you avoid needing to have your larynx removed.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT07417501RecruitingPhase 2
Lenvatinib plus immunotherapy for advanced cancers with 11q13 amplification
This trial tests a combination of two drugs, lenvatinib (a targeted therapy that stops blood vessel growth to tumors) and a PD-1 inhibitor (an immunotherapy that helps your immune system fight cancer), in people with advanced solid tumors that have a specific genetic change called 11q13 amplification. The goal is to see if this combination can shrink or control tumors that haven't responded to other treatments.
Wuhan, HubeiAges 18 years+ - NCT07419464RecruitingPhase 2
Testing 5-FU for head and neck cancer that has returned
This trial tests the drug 5-fluorouracil (5-FU) in people with head and neck cancer that has come back or spread. It aims to see if 5-FU can help when other treatments have stopped working.
St Louis, MissouriAges 18 years+ - NCT06613009RecruitingPhase 1
New Drug IBI3009 for Advanced Small Cell Lung Cancer
This trial tests a new drug called IBI3009 for people with advanced small cell lung cancer that cannot be removed by surgery. It aims to see how safe the drug is and how well it works against the cancer.
Westmead, New South WalesAges 18–75 - NCT03978078Recruiting
Database study for metastatic GI cancer care
This study collects clinical and lab information to better understand metastatic cancers of the digestive system and how patients respond to treatment. It may help improve future care, but it is mainly focused on collecting data rather than testing a new drug.
Montpellier, HéraultAges 18 years+ - NCT04823923Recruiting
How kidney failure affects drug levels in metastatic kidney cancer
This study looks at how chronic kidney failure changes the amount of certain cancer medicines in the blood. It involves people with metastatic clear cell kidney cancer who take pazopanib or cabozantinib, and compares drug levels in different kidney function groups.
MarseilleAges 18 years+
Hear when a new Pancreatic Adenocarcinoma Advanced or Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for pancreatic adenocarcinoma advanced or metastatic?
- Yes. Clin2 currently lists 3,839 recruiting pancreatic adenocarcinoma advanced or metastatic studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a pancreatic adenocarcinoma advanced or metastatic trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a pancreatic adenocarcinoma advanced or metastatic trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Metastatic Pancreatic Adenocarcinoma
- Locally Advanced Pancreatic Adenocarcinoma
- Metastatic Pancreatic Ductal Adenocarcinoma
- Locally Advanced Pancreatic Ductal Adenocarcinoma
- Advanced Pancreatic Ductal Adenocarcinoma
- Advanced Pancreatic Adenocarcinoma
- Pancreatic Ductal Adenocarcinoma
- Pancreatic Ductal Adenocarcinoma (PDAC)
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.